Gout flare prophylaxis during management of chronic gout with febuxostat, a non-purine selective inhibitor of xanthine oxidase.

被引：0
作者：
Wortmann, R
Becker, MA
Schumacher, HR
MacDonald, P
Palo, WA
Joseph-Ridge, N
机构：
[1] Univ Oklahoma, Tulsa, OK USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Univ Penn, VAMC, Philadelphia, PA 19104 USA
[4] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S335 / S336
页数：2
相关论文
共 50 条
[31]   Study on the activity of non-purine xanthine oxidase inhibitor by 3D-QSAR modeling and molecular docking [J].
Li, Peizhen ;
Tian, Yueli ;
Zhai, Honglin ;
Deng, Fangfang ;
Xie, Meihong ;
Zhang, Xiaoyun .
JOURNAL OF MOLECULAR STRUCTURE, 2013, 1051 :56-65
[32]   Febuxostat, a nonpurine selective inhibitor of xanthine oxidase: a promising medical therapy for chronic heart failure? [J].
Gao Ling-gen ;
Yao Xiu-ping ;
Zhang Lin ;
Wen Dan ;
Luo Fang ;
Zhou Xian-liang ;
Hui Ru-tai .
CHINESE MEDICAL JOURNAL, 2010, 123 (17) :2471-2474
[33]   Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout [J].
Huneycutt, Emily ;
Board, Chase ;
Clements, Jennifer N. .
JOURNAL OF PHARMACY PRACTICE, 2018, 31 (06) :670-677
[34]   In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase:: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition [J].
Mukoyoshi, M. ;
Nishimura, S. ;
Hoshide, S. ;
Umeda, S. ;
Kanou, M. ;
Taniguchi, K. ;
Muroga, H. .
XENOBIOTICA, 2008, 38 (05) :496-510
[35]   Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia [J].
Terkeltaub, Robert ;
Mune, JuneSik ;
Lee, Jieun ;
Saag, Kenneth .
ARTHRITIS & RHEUMATOLOGY, 2021, 73 :4093-4095
[36]   Impact of adding urine alkalization therapy to xanthine oxidase inhibitor in gout management: a prospective cohort study [J].
Wang, Can ;
Guo, Kai ;
Dalbeth, Nicola ;
Sun, Mingshu ;
Lu, Jie ;
Chen, Ying ;
Zhang, Hui ;
Wang, Xuefeng ;
Ji, Xiaopeng ;
Li, Xinde ;
Sun, Wenyan ;
Han, Lin ;
Cui, Lingling ;
Liu, Zhen ;
Ji, Aichang ;
He, Yuwei ;
Terkeltaub, Robert ;
Li, Changgui .
RHEUMATOLOGY, 2025, 64 (06) :3509-3517
[37]   Management of Acute Gout in Hospitalized Patients and Risk Factors for Xanthine Oxidase Inhibitor (XOI) Discontinuation or Dose Reduction [J].
Zhang, Dawen ;
Ko, Kichul ;
Becker, Michael A. ;
Jan, Reem .
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[38]   An Allopurinol-Controlled, Multicenter, Randomized, Open-Label, Parallel Between-Group, Comparative Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Hyperuricemia Including Those With Gout in Japan [J].
Naoyuki, Kamatani ;
Shin, Fujimori ;
Toshikazu, Hada ;
Tatsuo, Hosoya ;
Kenjiro, Kohri ;
Toshitaka, Nakamura ;
Takanori, Ueda ;
Tetsuya, Yamamoto ;
Hisashi, Yamanaka ;
Yuji, Matsuzawa .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (04) :S44-S49
[39]   A Repeated Oral Administration Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Impaired Renal Function in Japan [J].
Tatsuo, Hosoya ;
Iwao, Ohno .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (04) :S27-S34
[40]   Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine Oxidase/Xanthine dehydrogenase inhibitor, for gout and hyperuricemia. [J].
Kamatani, N ;
Fujimori, S ;
Hada, T ;
Hosoya, T ;
Kato, R ;
Matsuzawa, Y ;
Ueda, T .
ARTHRITIS AND RHEUMATISM, 2003, 48 (09) :S530-S530
12345